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Abstract
Background: Pre-eclampsia is associated with several complications. Early prediction of
complications and timely management is needed for clinical care of these patients to avert fetal and
maternal mortality and morbidity. There is a need to identify best testing strategies in pre eclampsia
to identify the women at increased risk of complications. We aim to determine the accuracy of
various tests to predict complications of pre-eclampsia by systematic quantitative reviews.
Method: We performed extensive search in MEDLINE (1951–2004), EMBASE (1974–2004) and
also will also include manual searches of bibliographies of primary and review articles. An initial
search has revealed 19500 citations. Two reviewers will independently select studies and extract
data on study characteristics, quality and accuracy. Accuracy data will be used to construct 2 × 2
tables. Data synthesis will involve assessment for heterogeneity and appropriately pooling of results
to produce summary Receiver Operating Characteristics (ROC) curve and summary likelihood
ratios.
Discussion: This review will generate predictive information and integrate that with therapeutic
effectiveness to determine the absolute benefit and harm of available therapy in reducing
complications in women with pre-eclampsia.
Background
Hypertension is a common medical complication of preg-
nancy, affecting about 6–8% of all pregnancies[1]. Hyper-
tensive disorders in pregnancy consist of a group of
disorders that include pre-eclampsia, latent or chronic
essential hypertension, a variety of renal diseases, and
transient (gestational) hypertension. The definitions used
to distinguish these disorders differ, leading to uncer-
tainty about their prevalence, natural history and
response to treatment. Pre eclampsia is associated with
several complications[2] and remains one of the largest
single cause of maternal and fetal mortality and morbid-
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ity[3,4]. They have been reported to account for 14% of
direct maternal deaths and 18% of fetal or infant
deaths[3,4].
Once the diagnosis of pre-eclampsia is established, timely
management is of the essence to avoid or minimise mor-
tality and morbidity. Clinical prediction of disease com-
plications using a combination of patients' characteristics,
symptoms, physical signs and investigations all of which
we consider tests, forms the basis of clinical care in these
situations[5]. Therefore, there is a need for guidance
regarding the best testing strategies with which to predict
the development of complications in pre-eclampsia. As
well as allowing clinicians to avoid unnecessary interven-
tions in low risk groups, this would allow high-risk groups
to benefit from monitoring of disease severity, use of anti-
hypertensive therapy, administration of anticonvulsants,
and antenatal corticosteroids[6,7].
Methods
A systematic quantitative overview of studies of complica-
tions of pre-eclampsia will be conducted to obtain sum-
mary estimates of accuracy of all available tests.
The proposed methodology is in line with the guidance of
the NHS Centre for Reviews and Dissemination[8] and
that of the Cochrane Methods Working Group on Screen-
ing and Diagnostic tests[9]. The investigation will be car-
ried out in the following recommended steps: (i)
Question formulation, (ii) Study selection and identifica-
tion, (iii) Study quality assessment, (iv) Data extraction
and (v) Data synthesis. Our strategy for each of these steps
will be based on a prospective protocol, which is outlined
below:
Question formulation
The tests to be considered by the review are specified in
the form of structured questions in Table 1. We have gen-
erated a priority list based on importance to clinical prac-
tice using a modified Delphi survey.[10] An exhaustive list
of the tests and outcomes in the prediction of pre eclamp-
sia were sent to experts in the field. Each one of the issues
were rated according to their importance to clinical prac-
tice and ranked accordingly. The review will focus on the
prioritised tests obtained from the survey.
Study identification and selection
We have a thorough search protocol by which literature is
identified via general bibliographic databases including
MEDLINE and EMBASE. Specialist computer databases
like DARE (Database Of Abstracts of Reviews of Effective-
ness), MEDION (a database of diagnostic test reviews set
up by Dutch and Belgian researchers), the Cochrane
Library and relevant specialist registers of the Cochrane
Collaboration, particularly the Pregnancy and Child Birth
group are searched. Individual experts and those with an
interest in this field will be contacted to uncover grey lit-
erature. SciSearch will be used to identify frequently cited
Table 1: Structured questions for systematic review of test accuracy studies
Question Components Tests for predicting complications of pre eclampsia
Population Pregnant women with pre eclampsia
Tests
History Parity; Race; Maternal age; Previous severe pre eclampsia/Eclampsia; Family history of pre eclampsia/
eclampsia; Obesity; Weight gain; Pre existing hypertension, renal disease, diabetes, lupus, thrombophilia, 
other auto immune diseases; Multiple pregnancy; Symptoms-headache, epigastric pain, nausea, visual 
disturbance or combination of symptoms
Examination Blood pressure; Peripheral oedema; Exaggerated tendon reflexes; Clonus; Papilloedema; Retinal changes; 
Oliguria; Symphysio fundal height; Oxygen saturation
Investigations Biochemical: Serum uric acid, urine dipstick (Bedside Urinalyses) 24 hour urine protein, urinary calcium 
excretion, hypoalbuminaemia, microalbuminuria, fibronectin, protinuria, renal and liver function tests; 
Ultrasound: Growth, liquor volume, Doppler (uterine, umbilical artery, Middle cerebral artery, venous, 
uteroplacental) Bio Physical Profile; Haematological: Anti thrombin III, platelet count, haemoglobin, 
fibrinogen, thrombophilia screen, Maternal serum Alpha feto protein(MSAFP), Serum Human Chorionic 
Gonadotropin (HCG); Computerised Tomography; Magnetic Resonance Imaging
Outcome Maternal
Eclampsia; Pulmonary oedema; Cerebral Haemorrhage; Hepatic, renal, haematological complications; 
Cardiac arrest; Abruption; Thromboembolism; stroke; psychiatric problems; Complications of labour and 
delivery; Maternal death; Need for hospitalisation, Day care unit visits, Use of intensive care, ventilation 
and dialysis
Fetal
Intra uterine growth restriction; Pre maturity; Abnormal p H at birth or antenatal; Abnormal Apgar; 
Hypoxic Ischemic Encephalopathy; Perinatal death; Long term effect, learning disabilities, Developmental 
and special needs after discharge; Need for neonatal intensive care admission, mechanical ventilation and 
duration of hospital stay
Study design Systematic review of test accuracy studies
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Table 2: Search term combinations for identification of studies predicting complications of pre eclampsia
Population Test Outcome
History Examination Investigation Final Refinement
1. pre adj eclampsia
2. preeclampsia
3. hypertens $
4. pregnan $
5. pre-eclampsia #.DE.
6. hypertension #.DE.
7. pregnancy #.DE.
8. 3 or 6 (hypertension)
9. 4 OR 7 (pregnancy)
10. 8 and 9 
(pregnancy and hypertension)
12. history
13. parity
14. multiparity or nulliparity
15. matern$ near age
16. (previous or prior) near 
eclampsia
17. (previous or prior) near 
preeclampsia
18. (previous or prior) near pre adj 
eclampsia
19. multiple near pregnan$*
20. twin$ or triplet$ or 
quadruplet$
21. symptom$
22. headache
23. epigastric near pain
24. naus$ or vomit$
25. race
26. diabet$
27. stress
28. lupus
29. thrombophilia
30. medical-history-taking#.DE.
31. maternal-age#.DE.
32. pregnancy-multiple#.DE.
33. headache#.DE.
34. signs-and-symptoms-
digestive#.DE.
35. vision-disorders#.DE.
36. weight gain#.DE.
37. population-groups#.DE.
38. diabetes-mellitus#.DE.
39. stress-psychological#.DE.
40. autoimmune-diseases#.DE.
41. thrombophilia#.DE.
43. blood adj pressure
44. oedema or edema
45. tendon$ near reflex$
46. hyperreflexia
47. clonus
48. papilledema or papilloedema
49. retina$ near change$
50. oliguria
51. symphys$ near fundal
52. symphys$ near height
53. cardiotocogra$
54. oxygen near saturat$
55. blood-pressure-
determination#.DE.
56. edema#.DE.
57. reflex-abnormal#.DE.
58. retinal-diseases#.DE.
59.oliguria#.DE.
60. cardiotocography#.DE.
61.oximetry#.DE.
63. serum near uric adj acid
64. urin near analys $
65. urin$
66. maternal near (feto adj 
protein$ or fetoprotein$ or 
alphafetoprotein$)
67. urin$ near calcium
68. hypoalbuminemia or 
hypoalbuminaemia
69. microalbuminuria
70. fibronectin$
71. proteinuria
72. renal adj function near test$
73. liver adj function near test$
74. liquor near volume
75. biophysical near profile
76. ultraso$
77. antithrombin$
78. platelet adj count
79. anti adj thrombin$
80. fibrinogen
81. antiphospholipid $
82. haemoglobin
83. uric-acid-QN.DE
84. alpha-fetoproteins #.DE
85. calcium-ur. DE
86. hypoalbuminemi a#.DE.
87. fibronectins .DE.
88. proteinuria #.DE.
89. kidney-function-test s#.DE.
90. liver-function-tests #.DE.
91. ultrasonography #.DE.
92. haematologic-test s#.DE.
93. antithrombin-III. DE.
94. fibrinogen #.DE.
95. antibodies-antiphospholipid 
#.DE.
96. diagnostic-imaging #.DE.
99. complicat$
100. (renal or kidney$) near 
(disease$ or complicat$)
101. (hepatic or liver$) near 
(disease$ or complicat$)
102. death or mortality
103. morbidity
104. eclampsia
105. (pulmonary or lung) near 
(complicat$ or disease$)
106. thromboembolism
107. pulmonary near
(oedema or edema)
108. ventilat$
109. stroke
110. uter$5 near haemorrhage
111. abruption
112. (heart or cardiac) near arrest$
113. (psychiatric or mental) near 
(illness$ or complication$1 or 
disorder)
114. hospitali$
115. hypox$ near isch$
116. (development$ or learning) near 
(disorder$ or difficult$)
117. pregnancy-complications#.DE.
118. kidney-diseases#.DE.
119. renal-dialysis#
120. liver-diseases#.DE.
121. death#
122. eclampsia#
123. pulmonary-embolism.DE.
124. respiration-artificial#
125. cerebrovascular-disorders#.DE.
126. brain-edema.DE.
127. intracranial-hypertension#.DE.
128. uterine-haemorrhage.DE.
129. abruption-placentae#.DE.
130. heart-diseases#
131. mood-disorders#.DE.
132. hospitalization#
133. infant-newborn-diseases#
134. respiratory-distress-syndrome-
newborn.DE.
135. mental-disorders-diagnosed-in-
childhood#.DE.
137. 11 and 98 and 136
(Captures Population and Test and 
Outcome)
138. animal = yes
139. human = yes
140. 138 not 139
141. 137 not 140
142. PT = comment or PT = letter
11. 1 OR 2 OR 5 OR 10
(Captures Population)
42. OR/12–41
(Captures history)
62. or/43–61
(Captures examination)
97. or/63–96
(Captures investigation)
136. or/99–135
(Captures Outcome)
143. 141 not 142
Final citation set (animal only 
studies, comments and letters 
excluded)
98. 42 or 62 or 97 (Captures Test)
Key to commands and codes used in Dialog interface:
Adj = words adjacent;; near = words within five words of each other in any order;.DE. = descriptor (MeSH heading);# = Exploded MeSH heading
$ = Truncated to allow for variant word endings; QN = Quick analysis pre-exploded subheading (including analysis, blood, urine, cerebrospinal fluid, isolation and purification PT = Publication Type
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articles. Hand-searching of selected specialist journals and
conference proceedings will be done to identify reports of
studies for the review. Reference lists of articles obtained
by iterative search will be checked as an adjunct to other
methods[11]. Language restrictions will not be applied. A
comprehensive database of relevant articles will be con-
structed. The search will be updated every year to enable
inclusion of current evidence in the reviews and including
other databases like SCOPUS where needed. A search
term combination was constructed after exhaustive plan-
ning and piloting of possible search concepts capturing
the relevant population, tests and outcomes. Our search
terms and flow chart of search strategy are shown in Table
2 and in Fig 1. An initial search in Medline yielded 11711
citations. The search strategy was adapted for searching in
Embase to obtain a total of 19500 citations. From this
citation set, studies will be selected for inclusion in the
review in a two-stage process.
Flow diagram of study selection process in Medlineigure 1
Flow diagram of study selection process in Medline.
TEST OUTCOM E
n=21218
POPULATION
OR
n=3789602
n=12527
n=11711
HISTORY EXAMINATION INV ESTIGATION
n=1750218 n=410518 n=1627858
Figure 1: Flow diagram of study selection process
Animal only, letters excluded
n=3387126
AND
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In the first stage the electronic searches will be scrutinised
by two independent reviewers and full manuscripts of all
citations that are likely to meet the predefined selection
criteria will be obtained. All available reports, irrespective
of language will be included to reduce bias[12]. Subse-
quent final inclusion or exclusion decisions will be made
on examination of these manuscripts. In cases of dupli-
cate publication, the most recent and complete versions
will be selected. Two reviewers will then independently
select the studies, which meet predefined and explicit cri-
teria regarding population, tests, outcomes and study
design (Table 1). These criteria will be piloted using a
sample of papers and agreement between reviewers will
be measured. When disagreements occur, the two review-
ers will meet and if necessary the issue will be resolved by
consensus involving a third reviewer.
Study quality assessment
A review of papers meeting the eligibility criteria will be
conducted by the same reviewers who judged eligibility,
but this time rating the methodological quality of the pri-
mary research. Methodological quality is a reflection of
the degree to which the study design, conduct and analysis
has minimised bias in addressing the research question.
This ensures a high level of internal validity (i.e. the
degree to which the results of an observation are correct
for the patients being studied). The potential sources of
bias and variability arising from spectrum composition
and other variations in test protocol or the use of reference
standard in individual studies will be considered when
interpreting the results[13]. In addition to using study
quality as possible explanation for differences in results,
the extent to which primary research met methodological
standards is important per se for assessing the strength of
any conclusions that are reached[8]. We will evaluate ele-
ments of study design which are likely to have a direct
relationship to bias and variability in a test accuracy study
[13-19]. The criteria for study validation are shown in Fig
2.
Criteria for quality assessment to be used in the review of tests predicting complications of pre eclampsiaFigu e 2
Criteria for quality assessment to be used in the review of tests predicting complications of pre eclampsia. 
a) Generic quality items   · Recruitment of subjects (consecutive or random sample)  · Blinding of observers assessing the out-
come to the findings of the test  · Verification of diagnosis by outcome in all tested cases  · 90% or more of enrolled population 
followed up    
b) Specific quality items related to features of this project   Population  Description of spectrum composition   Test Adequate 
description of test and its measurements determining cut-off level for abnormality a priori  Outcome Complications of pre 
eclampsia  
Study samp le
Test positive Test negative
Outcome 
present
True 
posit ive
Test
Outcome 
absent
False 
posit ive
Outcome
Outcome 
absent
True 
negative
Outcome 
present
False 
negative
The populat ion
A clinically appropriate 
consecutive or random 
sample
The test
Measurement
Cut-off for abnormality
Outcome
The Outcome
Assessment  blind to test 
result 
Verified fully in both test 
positive and test negative 
cases
Estimation  of  test  accuracy
e.g. likel ihood ratios
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Data extraction
The extraction of study findings will be conducted in
duplicate using a pre-designed and piloted data extraction
form to avoid any errors. Two authors will independently
extract information from each article in order to construct
2 × 2 tables of the diagnostic test result and outcomes. Any
disagreement will be resolved by consensus. Given the
extent of insufficient reporting in the medical literature,
we propose to obtain missing information from investiga-
tors whenever possible. It is otherwise impossible to dis-
tinguish between what was done but not reported and
what was not done. To avoid introducing bias, unpub-
lished information will be obtained in writing, and will be
coded in the same fashion as published information with
equal regard for inter-coder agreement. In addition to
using multiple coders to insure the reproducibility of the
overview, sensitivity analyses around important or ques-
tionable judgements regarding the inclusion or exclusion
of studies, the validity assessments and data extraction
will be performed.
Data synthesis
We will explore causes of variation in results from study to
study (heterogeneity), synthesise results from individual
studies (meta-analysis) if appropriate[8,15] and assess for
the risk of publication bias. Heterogeneity of results
between studies will be graphically assessed looking at the
distribution of rates, sensitivities and specificities in the
ROC (Receiver Operating Characteristics) curve and like-
lihood ratios using Forest plots. To explore causes of het-
erogeneity we will conduct a sensitivity analysis by
subgroups to see whether variations in population charac-
teristics, tests, outcomes and study quality affect the esti-
mate accuracy. Conclusions regarding the typical estimate
accuracy will be interpreted cautiously if there is signifi-
cant heterogeneity. Individual factors explaining hetero-
geneity will also be analysed using meta-regression to
determine their unique contribution allowing for other
factors. We will conduct meta-analyses to generate sum-
mary estimates of likelihood ratios (LRs), diagnostic odds
ratios (ratio of LRs) and area under receiver operating
characteristic (ROC) curves as appropriate[15,20,21]
The risk of publication bias is expected to be high in
reviews of test accuracy[22]. Analysis for assessing the risk
of publication bias will be carried out by producing fun-
nel plots of accuracy estimates against corresponding var-
iances. In the absence of publication bias it is to be
expected that the point estimates will fill a funnel shape in
the plot. Large gaps in the funnel indicate a group of pos-
sible 'missing' publications. These omissions are due to
small studies showing limited accuracy and are unlikely to
be missing at random. This phenomenon will also be sta-
tistically evaluated using Egger's test [23].
Discussion
In the same way as systematic reviews of effectiveness of
treatments in Obstetrics have been pursued over the last
decade, research on test accuracy also needs systematic
reviewing[14,24]. One of the questions remaining after
establishing effectiveness evidence for magnesium sul-
phate, steroids and anti hypertensives is to identify those
who will benefit most from these interventions[25,26].
Relying on the inclusion and exclusion criteria of the trials
alone is not sufficient for determining who should and
shouldn't get these treatments. Women at high risk of
complications of pre-eclampsia are likely to benefit most
whilst in low risk women, therapy may cause more harm
than good. Therefore, what is required is the prediction of
risk of complications (such as eclampsia) of pre-eclamp-
sia.
Information on women's risk stratification can be
obtained from test accuracy reviews, which provide post
test probabilities for a clinical outcome targeted by treat-
ment. Integration of these with evidence for therapeutic
effectiveness will enable generating estimates of Number
Needed to Treat (NNT). The lower the risk, the higher the
NNT and the lower are our and women's expectation of
benefit from treatment. Conversely, the higher the base-
line risk, the lower the NNT, the higher are our expecta-
tion of benefit and the more inclined we would be to
recommend, and women to accept therapy[24,27]. This
will serve to rationalise clinical decision-making.
This project will collate and synthesise the available evi-
dence regarding the value of the tests for predicting com-
plications of pre-eclampsia. The systematic overviews will
assess the quality of the available evidence and provide
estimates of rate (or risk) of complications of pre-eclamp-
sia given various patient characteristics and other find-
ings. It will identify a set of tests that have maximal
predictive value to aid in therapeutic decision-making. An
estimate of the magnitude of the benefits will be gauged
by integration of the knowledge about risk with evidence
of therapeutic effectiveness for various interventions. This
will help to formulate practice recommendations and spe-
cific recommendations for future research.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KSK conceived the idea of the review and developed the
protocol with KMKI, SO'B, FO'M, AC and ST. SS searched
the electronic databases to identify the studies. KMKI,
FO'M and SO'B obtained funding for ST from University
Hospital North Staffordshire Research and Development
Department, Stoke-on-Trent, UK. (Ref No. R 5177680).
All authors read and approved the final manuscript.
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Pregnancy and Childbirth 2008, 8:38 http://www.biomedcentral.com/1471-2393/8/38
Page 7 of 7
(page number not for citation purposes)
Acknowledgements
TIPPS review group
Shakila Thangaratinam (Clinical Lecturer), Khalid S Khan (Professor 
in Obstetrics and Gynaecology) affiliated to Education Resource Centre, 
Birmingham Women's Hospital, Birmingham, B15 2TG, UK.
Khaled M K Ismail (Senior Lecturer/Consultant), Fidelma O'Mahony 
(Senior Lecturer/Consultant), Shaughn O'Brien (Professor in Obstetrics 
and Gynaecology) affiliated to Academic Unit of Obstetrics and Gynaecol-
ogy, Keele University School of Medicine, University Hospital of North 
Staffordshire, Stoke-on-Trent, ST4 6QG, UK.
Steve Sharp (Electronic Information Librarian) affiliated to NeLH Special-
ist Library for ENT and Audiology, Radcliffe Infirmary, Oxford, OX2 6HE, 
UK.
Arri Coomarasamy (Sub specialist in Reproductive Medicine & Surgery) 
affiliated to Assisted Conception Unit, Guy's Hospital, London, UK
References
1. World Health Organization: The hypertensive disorders of preg-
nancy.  Report of a WHO Study Group; 1987. 
2. Duvekot JJ, Peeters LLH: Maternal haemodynamic adaptation
to pregnancy.  Obstet Gynecol Surv 1994, 49:S1-S14.
3. HMSO: Report on Confidential Enquiries into Maternal
Deaths in the United Kingdom 1997–99.  2001.
4. Montan SSNSN: Hypertension in Pregnancy – foetal and infant
outcome.  Hypertension in pregnancy 1987, B6:337-348.
5. Coomarasamy A, Papaiannou S, Gee , Khan KS: Aspirin to prevent
pre-eclampsia in women with abnormal uterine artery dop-
pler: a meta-analysis.  Obstet Gynecol 2001, 98:861-866.
6. Duley L, Henderson-Smart DJ, Knight M, King JF: Antiplatelet
drugs for prevention of pre-eclampsia and its consequences:
systematic review.  BMJ 2001, 322:329-333.
7. Coomarasamy A, Gee H, Khan KS, Braunholtz D: Aspirin has clin-
ically significant benefit in high risk groups – Summary NNT
can mislead clinicians.  eBMJ 2001.
8. Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J: Undertaking
Systematic Reviews of Research on Effectiveness.  In CRD's
Guidance for Carrying Out or Commissioning Reviews. 4. 2001 Centre for
Reviews and Dissemination (CRD), University of York. CRD Report. 
9. Cochrane Methods Working Group on Systematic Reviews
of Screening and Diagnostic Tests: Recommended Methods.
6-6-1996.  .
10. Thangaratinam S, Ismail K, Sharp S, Coomarasamy A, O'Mahony F,
Khan KS, O'Brien S: Prioritisation of tests for the prediction of
preeclampsia complications: a Delphi survey.  Hypertension in
Pregnancy 2007, 26:131-138.
11. Alderson P, Green S, Higgins JPT: Cochrane Reviewer's Hand-
book 4.2.2.  2004.
12. Egger M, Zellweger-Zahner T, et al.: Language bias in randomised
controlled trials published in English and German.  Lancet
1997, 350:326-329.
13. Whiting PJ, Rutjes AWS, Reitsma JB, Bossuyt PM, Glas Afina S, Klei-
jnen J: Sources of Variation and Bias in Studies of Diagnostic
Accuracy A Systematic Review.  Annals of Internal Medicine 2004,
40:189-202.
14. Khan KS, Dinnes J, Kleijnen J: Systematic reviews to evaluate
diagnostic tests.  J Obstet Gynecol Reprod Biol 2001, 95:6-11.
15. Deeks JJ: Systematic reviews in health care: Systematic
reviews of evaluations of diagnostic and screening tests.  BMJ
2001, 323:157-162.
16. Jaeschke R, Guyatt GH, Sackett DL: Users' guide to the medical
literature. II. How to use an article about a diagnostic test.
A. Are the results of the study valid?  JAMA 1994, 271:389-391.
17. Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, Meulen JHP
van der, et al.: Empirical evidence of design-related bias in
studies of diagnostic tests.  JAMA 1999, 282:1061-1066.
18. Bossuyt PM, Reitsma JB, Bruns DE, Glasziou PP, Gatsonis CA, Irwig
LM, et al.: Towards complete and accurate reporting of stud-
ies on diagnostic accuracy:The STARD initiative.  Family Prac-
tice 2004, 21:4-10.
19. Chein PFW, Khan KS: Evaluation of a clinical test. II: Assess-
ment of validity.  Br J Obstet Gynecol 2001, 108:568-572.
20. Jaeschke R, Guyatt GH, Sackett DL: Users' guide to the medical
literature. III. How to use an article about a diagnostic test.
B. What are the results and will they help me in caring for
my patients?  JAMA 1994, 271:703-707.
21. Honest H, Khan KS: Reporting of measures of accuracy in sys-
tematic reviews in diagnostic literature.  BMC Health Serv Res
2002, 2(1):4.
22. Song F, Khan KS, Dinnes J, Sutton A: Asymmetric Funnel Plots
and the Problem of Publication Bias in Meta-analyses of
Diagnostic Accuracy.  Int J Epidemiol 2002, 31:88-95.
23. Egger M, David SG, Schneider M, Minder C: Bias in meta analysis
detected by a simple, graphical test.  BMJ 1997, 315:629-34.
24. Khan KS, Honest , Bachmann LM: A generic framework for mak-
ing clinical decisions integrating diagnostic and therapeutic
research evidence in preterm birth. Fetal and Maternal Med-
icine Review.  Fetal and Maternal Medicine Review 2003, 13:239-249.
25. The Magpie Trial Collaborative Group: Do women with pre-
eclampsia, and their babies, benefit from magnesium sul-
phate? The Magpie Trial: a randomised placebo-controlled
trial.  Lancet 2002, 359(9321):1877-90.
26. Chein PFW, Khan KS, Arnott N: Magnesium sulphate in the
treatment of eclampsia and pre-eclampsia: an overview of
the evidence from randomised trials.  Br J Obstet Gynaecol 1996,
103(11):1085-91.
27. Coomarasamy A, Braunholtz D, Song F, Taylor R, Khan KS: Individ-
ualising use of aspirin to prevent pre eclampsia: A frame-
work for clinical decision making.  BJOG 2003, 110(10):882-888.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2393/8/38/prepub
